TY - JOUR
T1 - Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C
T2 - Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
AU - Yeon, Jong Eun
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2018/9/1
Y1 - 2018/9/1
N2 - The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions. Because of drug avalilability, cost-effectiveness, preference, compliance and greater possibility of desirable effects and presumed patient-important outcomes may vary between countries, treatment options for individual patients are different. The review focuses on the comparing the current treatment options for CHC in other continents with the 2017 Korea Association for the Study of the Liver guidelines.
AB - The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions. Because of drug avalilability, cost-effectiveness, preference, compliance and greater possibility of desirable effects and presumed patient-important outcomes may vary between countries, treatment options for individual patients are different. The review focuses on the comparing the current treatment options for CHC in other continents with the 2017 Korea Association for the Study of the Liver guidelines.
KW - Direct acting antiviral
KW - Genotype
KW - Hepatitis C virus
KW - Liver cirrhosis
KW - Resistance associated substitutions
UR - http://www.scopus.com/inward/record.url?scp=85054463144&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054463144&partnerID=8YFLogxK
U2 - 10.3350/cmh.2018.1002
DO - 10.3350/cmh.2018.1002
M3 - Article
C2 - 29716179
AN - SCOPUS:85054463144
VL - 24
SP - 278
EP - 293
JO - Clinical and molecular hepatology
JF - Clinical and molecular hepatology
SN - 2287-2728
IS - 3
ER -